ISSN: 2157-7609
Journal of Drug Metabolism & Toxicology
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
 
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Effect of Glutamate on Brain Iron Metabolism and the Regulation Mechanism

Peng Yu1,2*, Ming Zhang1,2, Hui Ding1, Xiaojing Di1, Peng Guan2, Shumin Wang1, Zhenhua Shi1, Dongyun Jiang1,2, Xianglin Duan1,2 and Yan-Zhong Chang1,2
1Laboratory of Molecular Iron Metabolism, College of Life Science, Hebei Normal University, Shijiazhuang, 050024, Hebei Province, People’s Republic of China
2Key laboratory of Animal Physiology, Biochemistry and Molecular Biology of Hebei Province, Hebei Normal University, Shijiazhuang 050024, Hebei Province, People’s Republic of China
Corresponding Author : Peng Yu
Ph.D, Associate Professor
Laboratory of Molecular Iron Metabolism
Hebei Normal University, Shijiazhuang
050024, Hebei Province, People’s Republic of China
Tel: 86-311-80786311
Fax: +86-311-80787507
E-mail: yupeng0311@mail.hebtu.edu.cn
Received: August 24, 2015 Accepted: September 19, 2015 Published: September 28, 2015
Citation: Yu P, Zhang M, Ding H, Di X, Guan P, et al. (2015) Effect of Glutamate on Brain Iron Metabolism and the Regulation Mechanism. J Drug Metab Toxicol 6:190. doi:10.4172/2157-7609.1000190
Copyright: © 2015 Yu P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at Pubmed, Scholar Google

Visit for more related articles at Journal of Drug Metabolism & Toxicology

Abstract

Glutamate is an excitatory transmitter and can induce neurotoxicity, it can also increase the iron concentrations in the brain, but little is known about the detailed molecular regulation mechanism of iron metabolism by Glu. Based on our previous data, iron metabolism related proteins might be associated with the increase of brain iron contents induced by neurotransmitter. To investigate the issues, the iron contents, non-transferrin-bound iron (NTBI) uptake and the expression of iron uptake and iron release proteins were firstly examined in vivo and in vitro with iron histochemistry, inductively coupled plasma mass spectroscopy (ICP-MS), 55Fe radioactive liquid scintillation counting and western blot methods. Data showed that glutamate induced the increase of total iron contents, storage iron contents and NTBI uptake activity. Moreover, only divalent metal transporter 1, one of iron uptake proteins, was increased in rat brain and PC12 cells treated with glutamate. Further investigations revealed that nuclear factor кB (NF-кB) and protein kinase C (PKC) were involved in the regulation of DMT1 in PC12 cells treated with glutamate. These findings demonstrate that glutamate increases iron contents in the brain through increased NTBI, and that DMT1 is the key molecule underlying regulation of iron metabolism by glutamate, Furthermore, NF-кB and PKC play important roles in the regulatory pathway of DMT1 expression by glutamate. Thus, it implicates that inhibiting the expression of DMT1 and disruption of its regulation pathway might be effective strategies in attenuating glutamate neurotoxicity through decreased iron contents.

Keywords
Divalent metal transporter 1; Nuclear factor кB; Protein kinase C; Glutamate; Iron; Rat
Abbreviations
AD: Alzheimer’s Disease; ALS: Amyotrophic Lateral Sclerosis; CLSM: Confocal Laser Scanning Microscope; DMT1: Divalent Metal Transporter 1; FPN1: Ferroportin 1; Glu: Glutamate; HD: Huntington’s Disease; ICP-MS: Inductively Coupled Plasma Mass Spectroscopy; IRE: Iron Responsive Element; FTL: L-Ferritin; Nds: Neurodegenerative Diseases; NF-Κb: Nuclear Factor Κb; NTBI: Non- Transferrin-Bound Iron; PD: Parkinson’s Disease; PDL: Poly-D-Lysine; PKC: Protein Kinase C; SFM: Serum-Free Medium; Tfr1: Transferrin Receptor 1
Introduction
It has been well known that glutamate (Glu) is an abundant excitatory transmitter in the brain [1,2]. However, high concentrations of glutamate and excessive stimulation of Glu-gated cation channels were also correlated closely with neurodegenerative diseases (NDs) including Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS) due to the neurotoxicity of glutamate [2-5]. It has been accepted that Glu induces excessive influx of Ca2+, which leads to subsequent intracellular cascade of cytotoxic events (such as nitric oxide production) and further exacerbates oxidative damage [6,7]. However, it is unknown if there are other mechanisms accounting for the excitotoxicity of glutamate.
Over the last decades, it has been confirmed that iron is essential for normal biochemical processes in the brain, such as oxygen transport, electron delivery, neurotransmitter synthesis, myelin production and maintenance [8]. However, in cases of PD, there is an increase in the total iron content of the substantia nigra, accompanied by the loss of nerve cells in the same regions [9,10]. The levels of iron are also significantly increased in the globus pallidus in Alzheimer’s disease (AD) and PD [11,12]. Iron overload and iron-induced oxidative stress constitute one of the mechanisms that are involved in the development of NDs such as PD and AD [13].
Earlier studies have recorded the relationship between iron and glutamate. It is reported that microinjection of excitatory amino acids inhibitor into the striatum of brain leads to alterations of iron concentrations in the ipsilateral globus pallidus and substantia nigra pars reticulate [14-16]. Our previous data also showed that the iron content was increased in the caudate putamen after microinjection of glutamate into substantia nigra [17]. While increased iron could induce oxidative damage to cells through Fenton reaction. These reports predicted new evidences for glutamate neurotoxicity from the role of iron metabolism. However, it is not well known how glutamate regulates the iron concentrations and the molecular mechanism in central nervous system.
Divalent Metal Transporter 1 (DMT1) is an important iron uptake protein in the brain [18,19], and its identification makes the investigation go into the molecular level. Ke et al. [20] found that DMT1 is distributed in different regions of rat brain and that development can significantly affect DMT1 expression in these areas. Our previous data [21] found that L-DOPA can significantly increase ferrous iron uptake and iron influx protein DMT1 expression in C6 cells, and that intranigral injection of glutamate induced the elevation of DMT1 protein level in the caudate putamen. All these seem to suggest that DMT1 might be a key molecule connecting iron and neurotransmitters. However, how glutamate regulates the expression of DMT1 in neuronal cells needs to be clarified.
PC12 cells, derived from rat pheochromocytoma, have been widely used as a neuron model in neurobiology and neuropharmacology because they have many properties in common with primary sympathetic neurons and chromaffin cell cultures [22]. Therefore, the present experiments were performed to detect the effect of glutamate on the iron contents, DMT1 expression and its regulatory mechanism in rat and PC12 cells. Results in this paper showed that glutamate can significantly increase iron contents through increased DMT1 expression accompanied by NTBI, and that NF-κB and PKC are involved in the regulation of DMT1 by glutamate.
Materials and Methods
Materials and reagents
The primary DMT1(+IRE)DMT1(-IRE) and FPN1 antibodies were purchased from ADI (ADI, San Antonio, TX, USA), the primary TfR1 antibody was from ZYMED (Invitrogen, Carlsbad, CA, USA), the primary FTL antibody was from Epitomics (Epitomics, Burlingame, CA, USA), the primary β-actin antibody was from Sigma (Sigma Chemical Co. St. Louis. Mo, USA), the primary NF-кB-p65 antibody was from Thermo-Fisher (Thermo-Fisher Scientific Inc., Rockford, USA), the primary H3 antibody was from Bioworld (1:500; bioworld, Louis park, USA). The secondary antibodies conjugated to horseradish peroxidase were purchased from Vector Labs (Burlingame, CA, USA); Dylight 488-conjugated secondary antibody was from Millipore (Temecula, CA, USA). Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum and horse serum were from Gibco (Gibco, Grand Island, NY, USA). BAY 11–7082 was from Enzo (ENZO Life Sciences, Inc., Farmingdale, NY, USA), Phorbol 12-myristate 13-acetate (PMA) and Chelerythrine chloride (CH) were from Amresco (Solon, OH, USA). All other chemicals and regents were purchased from Sigma and local commercial sources.
Animals and treatments
Male SD rats, purchased from HEB LAC (Hebei Medical University, China), were housed in cages at 21 ± 2°C and provided free access to food and water. Rooms were humidity controlled under a cycle of 12 h light and 12 h dark. All rats were allowed to adapt to their living conditions for 3 days before experiments.
For intracerebroventricular injection (ICV) of Glu, rats were anesthetized with pentobarbital sodium (40 mg/kg, i.p.), placed in a stereotaxic instrument (SR-6N, Tokyo, Japan) and Glu was injected as previously described, rostral~caudal: 0.8 mm posterior to Bregma, medial ~ lateral: 1.6 mm from the midline, and dorsal~ventral: 3.2 mm from the surface of the dura [23]. Sodium glutamate (Sigma) was administrated into rat lateral ventricle (60 μg and 120 μg, respectively), and the control group received the same volume of artificial cerebrospinal fluid (ACSF). 24 h later, cerebral cortex (CC), hippocampus (Hippo), substantia nigra (SN), cerebellum and striatum were dissected and collected for the following western blots and iron contents detection after rats were anesthetized and perfused with icecold normal saline.
All procedures were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals, and were approved by the Animal Care and Use Committee of Hebei Science and Technical Bureau in PRC.
Determination of non-heme iron contents in brain
CC, Hippo, cerebellum and striatum were dried for determining the non-heme iron contents as described previously [24,25]. Briefly, 0.6 M trichloroacetic acid in hydrochloride was added to brain samples at a ratio of 12.5 mL/g tissue (dry weight), and the tube was maintained at 65°C for 20 h. A clear acid extract was obtained after centrifugation at 12,000 g for 10 min. Then 4 μL of the acid extract and an equal volume of standard iron solution (1 mg/mL) were mixed with 200 μL of a Chromogen solution containing 0.2% thioglycolic acid and incubated for 10 min in a 96-well plate. Finally, the absorbance was read at 540 and iron levels were as previously described [25].
SN is small in sample size, so its iron contents was detected in cryostat sections with a modified Perl’s staining as previously described [23]. SN was cut at thickness of 20 μm and incubated at room temperature for 20 min in 1% H2O2 in 0.01 M phosphate-buffered saline (PBS) to quench endogenous peroxidase activity, then incubated at room temperature for 15 hr in a freshly made Perl’s solution [1% potassium ferrocyanide in 1% aqueous hydrochloric acid for ferric iron], and the negative control sections were incubated in Perl’s solution with PBS in place of potassium ferrocyanide. Finally, the sections were developed in a diaminobenzidine (DAB substrate kit SK-4100, Vector Laboratories) solution to enhance the staining of iron. To examine the morphology and detect the integrity of tissues, SN sections were stained in Nissle solution (1% cresyl violet, 0.5% toluidine blue and 0.25% thionine) at 50 for 100 s.
Cell culture
All experiments in vitro were performed using PC12 cells (ATCC No. 1721). The cells were maintained in DMEM culture medium including 10% horse serum, 5% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin. Cells were grown at 37°C in a humidified atmosphere containing 5% CO2 and subcultured every 5 ~ 6 d at a ratio of 1:5.
Measurement of the total iron contents in PC12 cells with ICP-MS
The total iron content was assayed in PC12 cells treated with different concentrations of Glu by Inductively Coupled Plasma Mass Spectroscopy (ICP-MS, Thermo Fisher, X Series, FL, USA [26]. After PC12 cells were incubated with different concentrations of glutamate, the medium was removed and the cells were washed with cold PBS. Then the cells were collected and added to 1 mL ultra-pure nitric acid (69.9–70.0%, J.T. Baker, USA) in Teflon digestion tubes, digested in the microwave digestion system for 2 h at 100°C, and then 4 h at 200°C. Standard curves ranging from 0 to 200 ppb were prepared by diluting iron standard with blanks prepared from homogenization reagents in 0.2% nitric acid. Standards and digested samples were read in triplicate by ICP-MS.
Measurement of non-transferrin-bound iron uptake with radioactive liquid scintillation counting
Iron-55 (55 FeCl3, Perkin-Elmer Life Sciences Company, MA, USA) solution was prepared by mixing 55 FeCl3 (10 mM in 0.5 M HCl) with FeSO4 (2 mM in 0.1 M HCl) in a molar ratio of 1:10, followed by a 50- fold molar excess of 2-mercaptoethanol and 0.27 M sucrose to give an iron concentration of 62.5 μM, as described previously [27,28]. After PC12 cells were incubated with Glu for 16 h in a CO2 incubator at 37°C, the cells (about 0.5 × 106 cells) were washed three times with icecold PBS (pH 7.4). The culture medium was then replaced with 0.5 mL solution which consisted of 0.27 M sucrose buffered to pH 6.4 ~ 6.5 with 4 mM Pipes. Then the radioactive iron solution was added into the sucrose solution to make a final iron concentration of 1.0 μM as determined previously [27]. Following our previous results, the incubations were performed at 37°C in a shaking water bath for 40 min. Then the cells were removed from the incubation solution, promptly washed three times with ice-cold PBS, and homogenized with buffer containing 1% SDS (500 μL) for 10 min at room temperature with shaking. 300 μL of the homogenate was taken for counting radioactivity with a Liquid Scintillation Analyzer (Packard, 2200 CA USA) and the remainder was used for protein assay with the Lowery method. The results were expressed as pmol Fe/min/mg of protein.
Preparation of the whole cell lysate and nuclear protein extraction
To extract the whole protein of cell lysate, rat brain tissues and PC12 cells were homogenized in RIPA buffer (containing 0.15 mM NaCl, 10 mM NaPO4, 1% Triton X-100 for cells or 1% NP-40 for tissues, 0.1% SDS, 0.1 mg/mL PMSF, 1 μg/mL aprotinin, 1 μg/mL leupeptin, and 1 μg/mL pepstatin) with a sonicator (Soniprep 150, MSE Scientific Instruments, England). After centrifugation of the homogenate at 10 000 g for 30 min at 4°C, the supernatant was collected and the total cell extract was obtained.
The nuclear isolation and extraction of PC12 cells was performed according to the method previously described [29]. Briefly, after PC12 cells were incubated with glutamate for 30 min, they were collected and re-suspended in Hypotonic Lysis Buffer (HLB, 10 mM Tris-Cl pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.2 mM PMSF, 1 mg/mL pepstatin, 1 mg/mL leupeptin and 1 mg/mL aprotinin). After a strong vortex for 10 s, the tubes were incubated for 10 ~ 15 min on ice to promote lysis, at this time the samples were stained with trypan blue to check with a microscope for >90% lysis. Then the tubes were centrifuged (15 min, 1 250 g, 4°C) and the nuclear fraction pellet was at the bottom of the centrifuge tube. Afterwards, the pellets were washed once with HLB, 1/2 packed nuclear volume of Low Salt Buffer (20 mM Tris-Cl pH 7.9, 25% Glycerol, 20 mM KCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.2 mM PMSF, 1% NP40, 1 mg/mL pepstatin, 1 mg/mL leupeptin and 1 mg/mL aprotinin) was added and stirred gently, then 1/2 packed nuclear volume of High Salt Buffer (20 mM Tris-Cl pH 7.9, 25% glycerol, 1.2 M KCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.2 mM PMSF, 1% NP-40, 1 mg/mL pepstatin, 1 mg/mL leupeptin and 1 mg/mL aprotinin) was added and kept on ice for 40 min, during which time strong vortex was carried out every 5 min. Finally, the tube was centrifuged at 14,000 g for 20 min at 4°C. The supernatants containing the nuclear extracts were obtained.
Western blot
About 30 μg of total proteins were separated using 10% SDS–PAGE gels and then transferred onto PVDF membranes (Hybond-P, Amersham Pharmacia Biotech) as previously described [30]. The blots were incubated with rabbit anti-rat DMT1 (−IRE)/ DMT1 (+IRE) / FPN1 antibody (1:5, 000), rabbit anti-rat FTL monoclonal antibody, rabbit anti-rat NF-κB-p65 antibody (1:1, 000), mouse anti-human TfR1 antibody (1:2,000) for 12 ~ 16 h at 4°C. Then the blots were incubated with anti-rabbit or anti-mouse secondary antibody conjugated to horseradish peroxide (1:5,000) for 1h at room temperature. Immunoreactive proteins were detected by enhanced chemiluminescence method (ECL kit, Pierce, USA). To ensure even loading of the samples, the same membrane was probed with rabbit anti-human β-actin antibody (1:5,000) for whole cell lysate or rabbit anti-rat H3 antibody (1:500) for nuclear extract protein. All raw values obtained were standardized to the endogenous control.
Immunocytochemistry
After PC12 cells climbed onto the glass slides coated with PDL, they were incubated with 1000 μM Glu for 30 min, 1 h, 2 h and 4 h. Then the medium were discarded and the PC12 cells on the slides were fixed with 4% paraformaldehyde in 0.1 M phosphate-buffer (PB, pH 7.2 ~ 7.4) overnight at 4°C. Next, the slides were washed in 0.01 M PBS (pH 7.4) and blocked with normal goat serum for 30 min at 37°C. After that, the slides were incubated in a primary mixture antibody containing rabbit anti-rat NF-κB-p65 antibody (1:150) for 24 h at 4°C. Then Dylight 488-conjugated secondary antibody (1:200) was added and kept in the dark for 60 min at 37°C. Subsequently DAPI was incubated for 5 min at room temperature. The slides were rinsed in PBS three times (5 min each) after every step. Finally, the slides were cover-slipped with glycerol and PBS at a ratio of 7:3. The slides were observed with a Confocal Laser Scanning Microscope (CLSM, Carl Zeiss LSMPascal 710, Zeiss, Oberkochen, Germany), and all images were digitally acquired using LSM software (ZEN2010).
Statistical Analysis
The data were expressed as means ± SD of 6 separate experiments. The differences between the means were determined using Statistical Product and Service Solutions (SPSS 21.0) followed by Post-Hoc Multiple Comparisons. The results were considered statistically significant with P<0.05.
Results
Glutamate increased iron contents in rat brain
To directly detect the effect of Glu on the iron levels in rat brain, striatum, Hippo, CC, cerebellum and SN were dissected for detection of non-haem iron contents. Data showed that Glu increased nonhaeme iron contents in Hippo, CC, cerebellum and SN (Figure 1A and 1B). We also detected the expression of iron storage protein L-ferritin (FTL), and found that Glu increased FTL expression in the brain (Figure 1C and 1D). This clearly implicated that glutamate increased the iron contents in the brain.
Glutamate increased the expression of DMT1 in rat brain
Iron homeostasis depends on iron uptake and iron export. Ferroportin 1 (FPN1) is commonly recognized as the iron release protein, transferrin Receptor 1 (TfR1) and DTM1 are responsible for iron uptake. Depending on the alternative splicing of iron responsive element (IRE) motif in the C-terminal, there are two isoforms of DMT1 protein named DMT1 (+IRE) and DMT1 (-IRE). To detect the mechanism underlying the increased iron contents in the brain, we detected the expression of TfR1, DMT1 and FPN1 in the brain after ICV of Glu. Data showed that DMT1 (+IRE) expression was increased significantly in SN, striatum, Hippo, CC and cerebellum (Figure 2). This indicated that the increased iron content in the brain might be mainly due to the increased expression of DMT1 protein after Glu treatment.
Glutamate increased the iron contents in PC12 cells
To detect the regulation mechanism of DMT1 expression by glutamate, PC12 cells were used as a neural model and incubated with different concentrations of glutamate. First, the iron storage protein FTL was detected with western blot analysis. Data showed that FTL was obviously increased after Glu treatment (Figure 3A). The total iron content of the PC12 cells was also determined by ICP-MS after they were treated with Glu. Data also showed that the total iron contents were increased significantly after treatment with 100 μM and 1000 μM concentrations of Glu (Figure 3B). The results were in accordance with data in vivo .
Glutamate enhanced the non-transferrin-bound iron (NTBI) uptake activity in PC12 cells
The results showed that the iron contents and the expression of DMT1 protein were both obviously increased in rat brain after Glu treatment. As is known, DMT1 plays the main role in NTBI uptake. To investigate or confirm if the increased iron contents in rat brain and PC12 cells was caused by the increase of iron uptake, 55Fe liquid scintillation counting method was used to detect the NTBI uptake in PC12 cells incubated with Glu. Data showed that there were significant increases in NTBI uptake activity in cells treated with 1 μM, 10 μM, 100 μM, 1000 μM Glu, compared with that of control groups (0 μM
Glutamate increased the expression of DMT1 in PC12 cells
To further determine if the increased iron contents and iron uptake were induced by the altered expression of iron metabolism related proteins, DMT1 (+IRE), DMT1 (-IRE), TfR1 and FPN1 were detected with western blot in PC12 cells. Data showed that there were significant increases in the expression of both DMT1 (+IRE) and DMT1 (-IRE) proteins in cells treated with 1 μM, 10 μM, 100 μM Glu (Figure 5A and 5B). While there were no changes in the expression of TfR1 and FPN1 protein (Figure 5C and 5D). These indicated that the elevated iron contents resulted from the increased iron uptake through increased expression of DMT1 protein.
The translocation of NF-кB was involved in the increased DMT1 expression of PC12 cells after glutamate treatment
Both DMT1 (+IRE) and DMT1 (-IRE) expression were increased in PC12 cells after they were treated with high concentrations of Glu. To investigate the regulation mechanism of DMT1 by Glu, the distribution and expression of NF-кB was examined in the nucleus of PC12 cells treated with 100 μM Glu for 15 min, 30 min, 1 h, 2 h and 4 h, respectively. The distribution of NF-кB was observed with CLSM after immunofluorescence staining. It was found that the staining of NF-кB appeared mainly in the cytoplasm in the control group, and its staining was partly appeared in the nuclei of PC12 cells treated with Glu (except for 4 h), especially the staining of NF-кB was most obvious after Glu treatment for 30 min. This means the distribution of NF-кB was translocated from the cytoplasm to the nucleus of PC12 cells (Figure 6). This indicated that glutamate induced the translocation of NF-кB in PC12 cells, which might suggest the activation of NF-кB signal pathway
To confirm the activation of NF-кB in the up-regulation of DMT1 by glutamate, BAY 11-7082 was used as an irreversible inhibitor of IкBα phosphorylation and can inhibit cytokine-induced NF-кB activation (Figure 2A). PC12 cells were pre-incubated with 5 μM Bay 11-7082 for 2 h, and then incubated with 100 μM Glu for 12 h, or along with 100 μM Glu for another 12 h. Data showed that Bay could inhibit the increased expression of DMT1 (+IRE) and DMT1 (-IRE) induced by glutamate through inhibition of NF-кB (Figure 7A). This suggested that glutamate might increase the DMT1 expression through NF-кB pathway.
PKC was also involved in the regulation of DMT1 by glutamate in PC12 cells
It is reported PKC regulate the expression of DMT1 through stabling DMT1 mRNA [31], so we detected the role of PKC in the regulation of DMT1 expression in PC12 cells treated with Glu. PMA was used as a PKC activator, and CH was used as a PKC inhibitor. Data found that PMA could increase DMT1 expression and CH could decrease DMT1 (+IRE) expression in PC12 cells, compared with that of Glu treatment (Figure 7B). This suggested that PKC might be involved in the regulation of DMT1 in PC12 cells treated with glutamate.
Discussion
It is reported that excessive glutamate can induce the burst influx of Ca2+ into cells and subsequent signal cascade events, which might cause oxidative damage and cell apoptosis even cell death. Several lines of evidences have showed that excitatory amino acid could affect iron accumulation in the brain [16,17]. It is known that iron can also cause oxidative damage through Fenton reaction, which might be another mechanism for glutamate neurotoxicity, but the detailed mechanism of the regulation has not been reported.
In order to investigate the possibility of the regulation of iron metabolism by glutamate, the iron concentrations, NTBI activity and iron transport protein expressions were examined in rat brain and PC12 cells. Data showed that Glu could increase iron levels in rat brain. Data also showed that glutamate decreased the cell viability obviously (Appendix 2) and that the total iron content was increased significantly in PC12 cells treated with Glu, which is in accordance with our results in vivo. Furthermore, the cellular storage of iron was also clearly increased. These data seem to imply that glutamate makes it much easier for more iron to enter cells. However, how glutamate induced the iron accumulation was still not clear.
Iron homeostasis mainly depends on the balance between iron uptake and iron release in a mammalian cells. DMT1 and TfR1 are key transporters for ferrous and ferric iron uptake, and FPN1 is the main iron exporter. The above data showed that iron was accumulated in rat brain and PC12 cells after glutamate treatment, so the expression of these iron transport proteins was examined with western blot analysis. Data showed that there were no changes in the expression of FPN1 and TfR1 protein, and that only the expression of DMT1 was significantly increased in brain and PC12 cells after glutamate treatment. At the same time, further experiment with radioactive 55Fe revealed that NTBI uptake was increased significantly as well. DMT1 has been well determined in the brain [20,32], and plays important roles in translocation of iron from endosome to cytosol in the transferrinbound iron uptake pathway and acquisition of NTBI by neurons [13,33]. Therefore, we deduced that the iron accumulation was the result of increased NTBI through increased DMT1 induced by glutamate. Studies by Cheah [34,35] revealed that DMT1 mediated the neurotoxicity of NMDA, and other reports also indicated that NMDA could increase DMT1 protein content after synaptic stimulation and improve their iron uptake capacity of primary hippocampus cultures [36]. These reports are in accordance with our results. However, how glutamate could regulate DMT1 is not fully elucidated.
It has been known that DMT1 expression depends on the IRE/IRP (iron responsive element-iron regulatory protein) regulatory system [37,38]. It is also reported that 6-OHDA can regulate the expression of DMT1 through the IRE/IRP system [39]. While our data did not show any evidence that DMT1 expression was regulated by glutamate through IRE/IRP system due to the following two reasons. First, there is no IRE motif in the 3’-untranslated region of DMT1 (-IRE) mRNA, so its expression cannot be regulated by the IRE/IRP regulatory system. Second, our data about DMT1 expression was not in accordance with the IRE/IRP regulatory theory. Because the iron content was also increased in PC12 cells treated with Glu, if this theory does work, the expression of DMT1 (+IRE) and DMT1 (-IRE) should be decreased, not increased obviously as indicated in our results. Therefore, the regulation of DMT1 expression by glutamate might not be dependent on IRE/IRP system, there must exist other regulatory mechanisms underlying the effect of glutamate on DMT1.
As is known, there are four isoforms of DMT1 [18], and the translocation of NF-κB from cytoplasm to nucleus and subsequent binding to the putative NF-κB response element within the 1B promoter of DMT1 increased the expression of DMT1 in undifferentiated P19 embryonic carcinoma cells [40-42]. Our data showed that glutamate can induce the translocation of NF-кB into the nucleus, which implicated the activation of NF-кB. The increased expression of DMT1 might be regulated by NF-кB. Further investigations were done by the application of BAY 11-7082, which can inhibit the activation of NF-кB due to its inhibition of IкBα phosphorylation and degradation. As expected, pre-treatment with BAY 11-7082 decreased the Glu-induced up-regulation of DMT1.
Therefore, NF-κB was involved in the up-regulation of DMT1 expression induced by Glu in PC12 cells. PKC can enhance the expression of DMT1 protein through inhibition of DMT1 mRNA degradation. Our data also showed that activation and inhibition of PKC resulted in the changes of DMT1 expression.
In conclusion, glutamate can increase iron contents in the brain, and the increased iron contents was due to the increased NTBI through increased DMT1. Moreover, NF-κB and PKC were involved in the regulation of DMT1 by glutamate. The induced iron accumulation in the brain would aggravate the oxidative damage through Fenton reaction, so as to result in glutamate excitotoxicity. This not only contribute to the understanding the mechanism of glutamate neurotoxicity from the view of iron metabolism, but also provide new molecular regulation evidences for the effect of glutamate on iron metabolism, which might give a new strategy in attenuating Glu neurotoxicity by inhibiting the expression of DMT1 through inactivation of NF-кB and PKC.
Acknowledgements
We are grateful to Professor Norman Davison, University of Manitoba, Winnipeg, Manitoba, Canada, for helpful discussions regarding the language.
The studies are supported by National Natural Science Foundation of China (31100822, 30871260 and 30870265), Natural Science Foundation of Hebei Province (C2012205068), Science Foundation of Hebei Education Department (2010145), and Doctoral Foundation of Hebei Normal University (L2006B22).
Conflict of Interest Statement
The authors declare that there are no conflicts of interest.
References
  1. Ende G (2015) Proton Magnetic Resonance Spectroscopy: Relevance of Glutamate and GABA to Neuropsychology. Neuropsychol Rev 25: 315-325.

  2. Choi DW (1988) Glutamate neurotoxicity and diseases of the nervous system. Neuron 1: 623-634.

  3. Coyle JT, Puttfarcken P (1993) Oxidative stress, glutamate, and neurodegenerative disorders. Science 262: 689-695.

  4. Parsons CG, Danysz W, Quack G (1998) Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect 11: 523-569.

  5. Moldzio R, Radad K, Krewenka C, Kranner B, Duvigneau JC, et al. (2013) Protective effects of resveratrol on glutamate-induced damages in murine brain cultures. J Neural Transm 120: 1271-1280.

  6. Gross NB, Duncker PC, Marshall JF (2011) Cortical ionotropic glutamate receptor antagonism protects against methamphetamine-induced striatal neurotoxicity. Neuroscience 199: 272-283.

  7. Kim EA, Choi J, Han AR, Choi SY, Hahn HG, et al. (2013) Anti-oxidative and anti-inflammatory effects of 2-cyclopropylimino-3-methyl-,3-thiazoline hydrochloride on glutamate-induced neurotoxicity in rat brain. Neurotoxicology 38: 106-114.

  8. Beard JL, Dawson H, Piñero DJ (1996) Iron metabolism: a comprehensive review. Nutr Rev 54: 295-317.

  9. Gibb WR, Lees AJ (1991) Anatomy, pigmentation, ventral and dorsal subpopulations of the substantianigra, and differential cell death in Parkinson's disease. J NeurolNeurosurg Psychiatry 54: 388-396.

  10. Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, et al. (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52: 1830-1836.

  11. Oakley AE, Collingwood JF, Dobson J, Love G, Perrott HR, et al. (2007) Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology 68: 1820-1825.

  12. Ward RJ, Dexter DT, Crichton RR (2012) Chelating agents for neurodegenerative diseases. Curr Med Chem 19: 2760-2772.

  13. Ke Y, Ming Qian Z (2003) Iron misregulation in the brain: a primary cause of neurodegenerative disorders. Lancet Neurol 2: 246-253.

  14. Hill JM (1985) Iron concentration reduced in ventral pallidum, globuspallidus, and substantianigra by GABA-transaminase inhibitor, gamma-vinyl GABA. Brain Res 342: 18-25.

  15. Morishita W, Xie Z, Chirwa SS, May PB, Sastry BR (1992) Blockade of hippocampal long-term potentiation by saccharin. Neuroscience 47: 21-31.

  16. Shoham S, Wertman E, Ebstein RP (1992) Iron accumulation in the rat basal ganglia after excitatory amino acid injections--dissociation from neuronal loss. ExpNeurol 118: 227-241.

  17. Guan P, Wang N, Duan XL, Chang YZ (2008) Effects of intranigral injection of glutamate and GABA on the expression of divalent metal transporter 1 and hephaestin in the caudate putamen nucleus of rats. ActaAnatomicaSinica 39: 795-799.

  18. Hubert N, Hentze MW (2002) Previously uncharacterized isoforms of divalent metal transporter (DMT)-1: Implications for regulation and cellular function. ProcNatlAcadSci U S A 99: 12345-12350.

  19. Jabado N, Canonne-Hergaux F, Gruenheid S, Picard V, Gros P (2002) Iron transporter Nramp2/DMT-1 is associated with the membrane of phagosomes in macrophages and Sertoli cells. Blood 100: 2617-2622.

  20. Ke Y, Chang YZ, Duan XL, Du JR, Zhu L, et al. (2005) Age-dependent and iron-independent expression of two mRNA isoforms of divalent metal transporter 1 in rat brain. Neurobiol Aging 26: 739-748.

  21. Chang YZ, Ke Y, Du JR, Halpern GM, Ho KP, et al. (2006) Increased divalent metal transporter 1 expression might be associated with the neurotoxicity of L-DOPA. MolPharmacol 69: 968-974.

  22. Greene LA, Tischler AS (1976) Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. ProcNatlAcadSci 73: 2424-2428.

  23. Yu P, Chang YZ, Miao W, Wang SM, Cui R, et al., (2009) Effects of intracerebroventricular injection of iron dextran on the iron concentration and divalent metal transporter 1 expression in the caudate putamen and substantianigra of rats. Anat Rec (Hoboken) 292: 225-233.

  24. Yuan L, Geng L, Ge L, Yu P, Duan X, et al. (2013) Effect of iron liposomes on anemia of inflammation. Int J Pharm 454: 82-89.

  25. Xu Z, Liu S, Wang H, Gao G, Yu P, et al. (2014) Encapsulation of iron in liposomes significantly improved the efficiency of iron supplementation in strenuously exercised rats. Biol Trace Elem Res 162: 181-188.

  26. Ding H, Yan CZ, Shi H, Zhao YS, Chang SY, et al. (2011) Hepcidin is involved in iron regulation in the ischemic brain. PLoS One 6: e25324.

  27. Chen Y, Qian ZM, Du J, Duan X, Chang Y, et al. (2005) Iron loading inhibits ferroportin1 expression in PC12 cells. NeurochemInt 47: 507-513.

  28. Kong WN, Zhao SE, Duan XL, Yang Z, Qian ZM, et al. (2008) Decreased DMT1 and increased ferroportin 1 expression is the mechanisms of reduced iron retention in macrophages by erythropoietin in rats. J Cell Biochem 104: 629-641.

  29. Abmayr SM, T Yao, T Parmely, JL Workman (2006)Preparation of nuclear and cytoplasmic extracts from mammalian cells. CurrProtocMolBiol, Chapter 12: p. Unit 12 11.

  30. You LH, Li F, Wang L, Zhao SE, Wang SM, et al. (2015) Brain iron accumulation exacerbates the pathogenesis of MPTP-induced Parkinson's disease. Neuroscience 284: 234-246.

  31. Olivi L, Sisk J, Bressler J (2001) Involvement of DMT1 in uptake of Cd in MDCK cells: role of protein kinase C. Am J Physiol Cell Physiol 281: C793-800.

  32. Burdo JR, Menzies SL, Simpson IA, Garrick LM, Garrick MD, et al. (2001) Distribution of divalent metal transporter 1 and metal transport protein 1 in the normal and Belgrade rat. J Neurosci Res 66: 1198-1207.

  33. Gunshin H, Allerson CR, Polycarpou-Schwarz M, Rofts A, Rogers JT, et al. (2001) Iron-dependent regulation of the divalent metal ion transporter. FEBS Lett 509: 309-316.

  34. Cheah JH, Kim SF, Hester LD, Clancy KW, Patterson SE 3rd, et al. (2006) NMDA receptor-nitric oxide transmission mediates neuronal iron homeostasis via the GTPase Dexras1. Neuron 51: 431-440.

  35. Chen Y, Khan RS, Cwanger A, Song Y, Steenstra C, et al. (2013) Dexras, a small GTPase, is required for glutamate-NMDA neurotoxicity. J Neurosci 33: 3582-3587.

  36. Haeger P, Alvarez A, Leal N, Adasme T, Nunez MT (2010) Increased hippocampal expression of the divalent metal transporter 1 (DMT1) mRNA variants 1B and +IRE and DMT1 protein after NMDA-receptor stimulation or spatial memory training. Neurotox Res 17: 238-247

  37. Muckenthaler MU, Galy B, Hentze MW (2008) Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. Annu Rev Nutr 28: 197-213.

  38. Yu P, ZM Qian, Duan XL, Chang YZ (2004) The structure of DMT1 and its regulatory mechanism. Chinese Journal of Neuroanatomy 20: 205-209.

  39. Jiang H, Song N, Xu H, Zhang S, Wang J, et al. (2010) Up-regulation of divalent metal transporter 1 in 6-hydroxydopamine intoxication is IRE/IRP dependent. Cell Res 20: 345-356.

  40. Paradkar PN, Roth JA (2006) Nitric oxide transcriptionally down-regulates specific isoforms of divalent metal transporter (DMT1) via NF-kappaB. J Neurochem 96: 1768-1777.

  41. Paradkar PN, Roth JA (2006) Post-translational and transcriptional regulation of DMT1 during P19 embryonic carcinoma cell differentiation by retinoic acid. Biochem J 394: 173-183.

  42. Xu H, Jiang H, Wang J, Xie J (2010) Rg1 protects the MPP+-treated MES23.5 cells via attenuating DMT1 up-regulation and cellular iron uptake. Neuropharmacology 58: 488-494.

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11282
  • [From(publication date):
    October-2015 - Jul 26, 2016]
  • Breakdown by view type
  • HTML page views : 7534
  • PDF downloads :3748
 
 
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

OMICS International Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
 
 
OMICS International Conferences 2016-17
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings
 
 

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsinc.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsinc.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsinc.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsinc.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsinc.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsinc.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsinc.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsinc.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsinc.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsinc.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsinc.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsinc.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsinc.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsinc.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsinc.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsinc.com

1-702-714-7001 Extn: 9042

 
© 2008-2016 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version